Table IV.
No. (%) of patients receiving central nervous system (CNS)–active medications in the adverse-drug-reaction (ADR) and control groups.∗†
| Drug/Class | ADR (n = 25) | Control (n = 29) |
|---|---|---|
| Carbidopa and levodopa | 6 (24.0) | 2 (6.9) |
| Selective serotonin reuptake inhibitors | 4 (16.0) | 3 (10.3) |
| Antipsychotics | 3 (12.0) | 4 (13.8) |
| Tricyclic antidepressants | 2 (8.0) | 2 (6.9) |
| Phenytoin | 1 (4.0) | 2 (6.9) |
| Benzodiazepines | 1 (4.0) | 1 (3.4) |
| Narcotics | 1 (4.0) | 1 (3.4) |
| Gabapentin | 1 (4.0) | 0 (0.0) |
| Valproic acid | 0 (0.0) | 1 (3.4) |
∗
Some patients were receiving >1 CNS drug.
†
No significant between-group differences were found.